Concepedia

Daniel Gusenleitner

DG

Statistics

Publications

23

Citations

3K

H-Index

19

Active since

2011

Affiliations

Dana-Farber Cancer Institute(Current)

Novartis (United States)

Harvard University

Boston University

Massachusetts General Hospital

Daniel Gusenleitner is an author at Dana-Farber Cancer Institute specializing in oncology, immunology, and medicine.

ORCID

Top concepts

Publications per year

2011–2024

23

Publications

23

Targetable genetic features of primary testicular and primary central nervous system lymphomas

Bjoern Chapuy, Margaretha G.M. Roemer, Chip Stewart et al. · Blood · 2015 · 590 citations · Full text

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

Scott J. Rodig, Daniel Gusenleitner, Donald Jackson et al. · Science Translational Medicine · 2018 · 567 citations

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma

Christopher D. Carey, Daniel Gusenleitner, Mikel Lipschitz et al. · Blood · 2017 · 325 citations · Full text

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Priyanka B. Subrahmanyam, Zhiwan Dong, Daniel Gusenleitner et al. · Journal for ImmunoTherapy of Cancer · 2018 · 188 citations · Full text

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade

Sachet A. Shukla, Pavan Bachireddy, Bastian Schilling et al. · Cell · 2018 · 167 citations · Full text

, , +5

Rows per page

1–5 of 23